Navigation Links
Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful complication of shingles, affects approximately 200,000 people a year in the US alone. The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with PHN. Solace anticipates having results from the study in the second half of 2009.

SLC022 is an orally administered glial cell modulator that has shown efficacy in well-established preclinical pain models. Glial cells represent an important new target for the treatment of chronic pain based on their active role in neuronal pain signaling.

"The initiation of this study is another important milestone for Solace in our drive to discover and develop innovative treatments for pain," said Dr. Eliot Forster, Solace's Chief Executive Officer. "Our confidence in SLC022 is underpinned by a large body of prior preclinical and clinical data generated during the compound's previous development in a non-pain indication. We believe these data lower the development risk and enhance the opportunity for a favorable clinical profile."

Solace's advancement of SLC022 caps a year of significant progress. In 2008, Solace expanded its glial cell modulator program by identifying next-generation, novel leads with attractive drug properties. The company made equally rapid progress in optimizing inhibitors of the enzyme GTP cyclohydrolase 1 (GCH1), a key target within the BH4 synthesis pathway, and in identifying additional promising drug targets.

Solace Pharmaceuticals also established a two-year collaboration with Professor Keith Channon, MD FRCP, of the Department of Cardio
'/>"/>

SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
8. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 A lot of discussion in the medical community ... illnesses, injuries, or conditions. As medical science advances, doctors and ... ones that they consider to be more cutting edge. Yet, ... textbook method of treatment that stands out as the best ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ... directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... breached its fiduciary duties to shareholders. On ... investing website reporting that Advaxis had misrepresented the clinical ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN; NYSE: ... completed the previously announced acquisition of BMP Sunstone Corporation ... today, BMP Sunstone stockholders approved the adoption of the ... Inc., a wholly owned subsidiary of sanofi-aventis, dated October ...
... BrainScope Company, Inc. today announced that Peter ... Medical Advisory Board.  He holds the distinguished title ... the University of Edinburgh, Scotland, United Kingdom.  This ... is entering the U.K. market with its "B-Ahead ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2BrainScope® Announces Appointment of Professor Peter Andrews, MD to Its Medical Advisory Board 2BrainScope® Announces Appointment of Professor Peter Andrews, MD to Its Medical Advisory Board 3BrainScope® Announces Appointment of Professor Peter Andrews, MD to Its Medical Advisory Board 4
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... Step into a macabre world where plants hold ... Wicked Plants, the Museum’s latest featured exhibition, opens Saturday, ... and diabolical plants inside of a dilapidated, Victorian home. ... physical and neurological processes between botanicals and the human ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... in German . , On 7 ... in Health Care (IQWiG) published the results of a ... heart disease (CHD). The aim of the report is ... methodological quality that may be relevant for the planned ...
... undergoing radiation treatments for head and neck cancer fare ... according to a study in the February issue of ... official journal of the American Society for Radiation Oncology ... smoking and head and neck cancers has long been ...
... have discovered a novel function of brain insulin, indicating that ... unrestrained lipolysis that initiates and worsens type 2 diabetes in ... Cell Metabolism . Led by Christoph Buettner, MD, ... and Bone Disease at Mount Sinai School of Medicine, the ...
... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) -- ... they,re first tested may not need to be screened annually ... study suggests. Dutch researchers presenting the findings at ... men with a PSA below 3.0 ng/ml were likely to ...
... Feb. 15 (HealthDay News) -- Men with prostate cancer may be ... baldness at the age of 20 than those without prostate cancer, ... hair in their 30s or 40s do not appear to face ... loss starts in their 20s do not face a higher risk ...
... more likely to be readmitted to the hospital after a ... pneumonia, according to a new study from Harvard School of ... rates were due to disparities related to both race and ... health and health care are well-documented in this country, but ...
Cached Medicine News:Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 3Health News:Smoking during radiation treatments reduces chance of overall survival 2Health News:Researchers find brain insulin plays critical role in the development of diabetes 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 3Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 2Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 3Health News:Study finds blacks more likely to be readmitted to hospitals after discharge 2
... TME 227 T is a ... temporary cardiac pacing and monitoring ... The TME 227 T features ... myocardium, which allows safe and ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: